Prodrug for the treatment of disease and injury of oxidative stress
OwnerG. Michael Wallinventor
Life of this patent
Estimating the term…
Loading patent…
OwnerG. Michael Wallinventor
Estimating the term…
The present invention includes a method for using diNACA as a prodrug to deliver diNACA, NACA and NAC to a mammal for therapeutic purposes to prevent or treat diseases or disorders involving oxidative stress. The method includes any disease that involves the therapeutic use of NACA or NAC as a therapeutic agent. Also, compositions and methods for the prevention, reduction or treatment of corneal endothelial cell loss in a patient that comprise providing the patient with an amount of at least one, alone or in combination, of N-acetylcysteine amide (NACA) or (2R,2R′)-3,3′-disulfanediyl bis(2-acetamidopropanamide) (diNACA) (diNACA) to prevent or reduce the corneal endothelial cell loss or to prevent or treat presbyopia. DiNACA can be used to prevent or treat cataracts.
A method for using diNACA as a prodrug to deliver diNACA, NACA or NAC to treat diseases or disorders of oxidative stress in a mammal comprising, consisting essentially of, or consisting of:
A method for the prevention of corneal endothelial cell loss in a human subject comprising:
A method for the prevention or reduction of presbyopia in a human subject comprising:
The method of claim 16, wherein the dose for administration is about 0.001, 0.01, 0.1, 1, 10, 100, 150, 150, 300, 333, 400, 500, 600, 700, 750, 800, 900, 1,000, 2,500, 5,000, 7,500, or 10,000 mg per dose. 39. The method of claim 323, wherein at least one of NAC, NACA or diNACA is delivered orally via a mini-tablet, capsule, tablet, effervescent, dual release, mixed release, sachet, powder, or liquid.
A method for the prevention or reduction of cataract by providing a subject in need thereof a therapeutically effective amount of diNACA and administering to the human patient a therapeutically effective amount of diNACA to prevent or treat cataract.
Dependencies are inferred from the claim text.